The health tech pioneer, co-founded by Spotify’s Daniel Ek, is set to disrupt the American preventive care landscape following a massive Series C funding round that brings its total valuation and capital raised to over $1 billion.
Neko Health, the Swedish-born diagnostic technology company, has officially announced plans to enter the United States market this year. This expansion, centered on the upcoming launch of a flagship New York clinic, follows a monumental $700 million Series C financing round. The investment not only underscores the growing appetite for high-tech, proactive healthcare but also signals a major shift in how diagnostic data is gathered and interpreted for the general public.
Main Facts: A New Frontier in Diagnostic Medicine
Neko Health has positioned itself at the intersection of consumer technology and clinical diagnostics. Its core product, the "Neko Health Scan," is a non-invasive, high-throughput diagnostic chamber that utilizes a sophisticated array of 70 sensors to map roughly 50 million health data points in a single session.
The company’s model is built on the philosophy of "preventative longevity"—catching potential health issues before they become symptomatic. By combining high-resolution thermal imaging, 2D and 3D body photography, and advanced metabolic sensors, Neko provides users with a comprehensive snapshot of their physiological status.
With this latest $700 million injection, the company has now surpassed $1 billion in total funding. The round was led by Lightspeed Venture Partners and O.G. Venture Partners, with significant participation from high-profile backers including Liberty City Ventures, Positive Sum, Meta CEO Mark Zuckerberg, and football legend Thierry Henry. This capital will be utilized to accelerate the rollout of US clinics, scale the underlying AI diagnostic infrastructure, and continue the research and development of its proprietary scanning technology.
The Chronology of Growth: From Stockholm to the World
The trajectory of Neko Health since its inception in 2018 has been marked by rapid scaling and a disciplined approach to operational expansion.
- 2018: Hjalmar Nilsonne and Daniel Ek (co-founder and former CEO of Spotify) launch Neko Health in Stockholm, Sweden, with the vision of making advanced health monitoring accessible and affordable.
- 2023: The company officially opens its first commercial clinic in Stockholm. The service gains immediate traction, proving the viability of its high-tech, data-heavy diagnostic model.
- September 2024: Following European success, Neko launches its first UK site in Marylebone, London. This move marked the beginning of its international scaling phase.
- 2024–2025: Neko expands its UK footprint, adding three additional locations in London, as well as sites in Birmingham and Manchester.
- January 2025: The company successfully closes a $260 million Series B funding round, demonstrating sustained investor confidence.
- March 2026: In a strategic move to prepare for US regulatory and operational demands, the company appoints Dr. Sunita Mishra, former CMO at Amazon Health, as its new Chief Medical Officer.
- Late 2026: Neko Health announces its $700 million Series C round and confirms the imminent launch of its first United States location in New York City.
Supporting Data: By the Numbers
The success of Neko Health is not merely theoretical; it is backed by significant user demand and clinical engagement metrics.
- Total Capital Raised: Over $1 billion.
- User Base: More than 100,000 individuals across the UK and Sweden have already completed a full-body scan.
- Waitlist Momentum: Over 350,000 people are currently registered on the company’s waitlist, indicating a massive latent demand for their specific brand of preventative screening.
- The Scan Experience: A typical session lasts 60 minutes and is priced at £299 (UK) or 2,750 SEK (Sweden).
- Technological Scale: Each scan processes 50 million data points using 70 proprietary sensors.
Recent updates to the scanning technology have introduced advanced body composition metrics and the integration of clinician-reviewed wearable data. This holistic approach ensures that the "snapshot" provided during a clinic visit is supplemented by continuous monitoring between appointments, providing a more longitudinal view of the patient’s health trajectory.
Clinical Methodology: What Happens Inside the Chamber?
Neko Health’s clinical methodology is designed to be as frictionless as possible while providing deep diagnostic utility. Upon entering the chamber, users undergo a comprehensive assessment that evaluates:
- Skin Health: Utilizing high-resolution imagery to detect changes in lesions or moles that may indicate dermatological risks.
- Metabolic Composition: Analyzing biomarkers to identify risks for conditions such as pre-diabetes, metabolic syndrome, and other blood-related abnormalities.
- Cardiovascular Risk Factors: Assessing data points linked to heart health, including indicators that might predict the risk of stroke or heart attack.
Perhaps the most significant differentiator is the speed of feedback. Patients typically receive their results during a consultation immediately following the scan, facilitated by the company’s clinical staff. This immediacy addresses one of the primary pain points in traditional healthcare: the long, anxiety-inducing waiting periods for test results.
Official Responses: Leadership Perspectives
The infusion of capital has been met with optimism by Neko’s leadership, who view this as a validation of their long-term mission to transition medicine from reactive to proactive.
Hjalmar Nilsonne, CEO and co-founder of Neko Health, emphasized the significance of the Series C round:
"This funding is a strong vote of confidence in what we set out to do when we opened our first clinic three years ago: a completely new healthcare experience designed to keep people healthy, catch problems early, and help prevent disease before it even starts. With this round, we’re taking that mission to the US for the first time, while continuing to invest in the research and technology that make prevention possible at scale."
The appointment of Dr. Sunita Mishra as CMO further solidifies this focus. By leveraging her experience at Amazon Health, Neko is positioning itself to navigate the complex US regulatory environment while ensuring that its clinical outcomes remain at the highest standard.
Implications: The Future of Preventative Care
The entry of Neko Health into the US market carries several profound implications for the global healthcare sector.
1. The Normalization of "Health Audits"
Neko is essentially pioneering a new consumer category: the "annual health audit." By providing a comprehensive, data-driven report card of an individual’s health, they are encouraging a cultural shift where patients take an active, quantified interest in their biological markers.
2. Pressure on Traditional Systems
The traditional primary care model is often criticized for being overburdened and reactive. By offering a high-tech alternative that catches pathologies in their nascent stages, Neko may force traditional insurers and healthcare providers to rethink their own preventative care offerings. If consumers begin to expect 50-million-point data sets as part of their routine care, the "status quo" of infrequent, symptomatic-based testing may no longer suffice.
3. The Role of AI in Diagnostic Accuracy
The reliance on AI to synthesize thermal, photographic, and metabolic data highlights the growing trend of "augmented medicine." As the technology scales, the data pool will grow, allowing Neko’s algorithms to become increasingly accurate at detecting anomalies that might be missed by the human eye or standard laboratory tests.
4. Regulatory and Ethical Challenges
As Neko moves into the US, it will face a unique set of challenges, including HIPAA compliance, rigorous FDA scrutiny regarding medical device efficacy, and the ethical implications of data privacy for such an extensive biological map. The company’s success will depend on its ability to maintain public trust while proving that its "preventative" findings are not only accurate but also actionable by the broader medical community.
Conclusion
With over $1 billion in backing and a proven model in Europe, Neko Health is no longer a niche startup; it is a serious contender in the future of global medicine. As the company prepares to open its doors in New York, the industry will be watching closely to see if the "Neko effect"—the transition to data-heavy, proactive health monitoring—can successfully take root in the complex American healthcare ecosystem. For patients, the promise is clear: a future where the onset of disease is no longer a surprise, but a manageable data point.
About the Author
